Protagenic Therapeutics, Inc.\new (PTIX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Mar 31
In fiscal 2024, Protagenic Therapeutics, Inc.\new reported revenue of $0. The company ran a net loss. It held $1.96M in total assets against $942.8K in total liabilities.
Key ratios (FY2024)
-545.4%
Return on equity
| Metric (FY) | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | — | — | — | $0 | $0 |
| Operating Income | -$5.70M | -$4.53M | -$3.56M | -$4.14M | -$2.55M | -$2.09M | -$2.31M | -$2.37M | -$2.23M | -$1.03M |
| Net Income | -$5.53M | -$5.00M | -$3.56M | -$4.52M | -$2.55M | -$1.75M | -$2.56M | -$2.26M | -$2.28M | -$1.02M |
| EPS (Diluted) | $-1.13 | $-1.15 | $-0.82 | $-1.24 | — | — | — | — | — | — |
| Total Assets | $1.96M | $4.32M | $8.04M | $11.06M | $879.2K | $842.3K | $696.9K | $1.78M | $3.16M | $11.1K |
| Total Liabilities | $942.8K | $655.3K | $1.12M | $1.12M | $2.03M | $1.48M | $907.8K | — | — | $704.0K |
| Shareholders' Equity | $1.01M | $3.67M | $6.92M | $9.94M | -$1.15M | -$634.4K | -$210.9K | $1.22M | $2.48M | -$667.2K |
| Cash & Equivalents | — | — | — | — | $671.1K | $798.6K | $362.5K | $399.7K | $3.10M | $3.3K |
| Operating Cash Flow | -$4.22M | -$3.70M | -$1.99M | -$2.80M | -$1.35M | -$488.0K | -$1.07M | -$1.38M | -$1.14M | — |
| Capital Expenditures | — | $149.8K | $1.8K | — | — | — | — | — | — | — |
| Shares Outstanding | 7.24M | 4.44M | 4.32M | 4.30M | 10.36M | 10.26M | 10.26M | 10.26M | 10.26M | 6.61M |